Evidence map›Paper›PMID 40820736›Full record

ArticleHaematologica2026

FOXM1 down-regulation is a trigger of isatuximab-induced direct cell death in multiple myeloma cells with 1q.

Jiro Kikuchi, Naoki Osada, Sae Matsuoka, Tomomi Ohta, Hirotaka Kazama, Heigoro Shirai, Marco Meloni, Marielle Chiron, Hiroshi Yasui, Hideki Nakasone and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiro KikuchiDivision of Emerging Medicine for Integrated Therapeutics (EMIT), Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498. kiku-j@jichi.ac.jp.
Naoki OsadaDivision of Emerging Medicine for Integrated Therapeutics (EMIT), Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498.
Sae MatsuokaDivision of Emerging Medicine for Integrated Therapeutics (EMIT), Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498.
Tomomi OhtaSANOFI Oncology Medical, Tokyo 163-1488.
Hirotaka KazamaSANOFI Oncology Medical, Tokyo 163-1488.
Heigoro ShiraiSANOFI Oncology Medical, Tokyo 163-1488.
Marco MeloniSANOFI RD, Vitry-sur-Seine.
Marielle ChironSANOFI RD, Vitry-sur-Seine.
Hiroshi YasuiDepartment of Hematology/Oncology, The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; Department of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki 216-8511 Japan.
Hideki NakasoneDivision of Emerging Medicine for Integrated Therapeutics (EMIT), Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498.
Yusuke FurukawaDivision of Emerging Medicine for Integrated Therapeutics (EMIT), Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan; Center for Medical Education, Teikyo University of Science, Tokyo 120-0045.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40820736
PMCPMC12775791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.